Akriti Gupta Jain
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Akriti Gupta Jain has a total of 239 co-authors. Here are the top co-authors by number of shared publications:
- Kendra Sweet
H. Lee Moffitt Cancer Center and Research Institute Tampa Florida USA
12 shared publications - Rami Komrokji
H. Lee Moffitt Cancer Center, Tampa, Florida, United States
12 shared publications - David A. Sallman
Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
11 shared publications Eric Padron
H. Lee Moffitt Cancer Center and Research Institute Tampa Florida USA
9 shared publications- Jeffrey Lancet
H. Lee Moffitt Cancer Center and Research Institute
8 shared publications - Andrew Kuykendall
Moffitt Cancer Center, Tampa, USA
7 shared publications
Latest Publications
- Open Access
- 3 November 2026
- Published by Springer Nature in Leukemia
- p. 1-9
Salvage therapy for immune-mediated bone marrow failure
Most acquired idiopathic bone marrow failure syndromes (BMFS) are thought to be cytotoxic T cell-mediated and are responsive to immunosuppressive therapies (IST) targeting T cells. However, in addition to frequent relapses, a proportion of cases remain refractory to first- and second-line agents due to a lack of clinical trials in the refractory and relapsed disease setting. Recently, the landscape of IST has expanded significantly, harnessing multiple molecular pathways that could be theoretically useful in the BMFS setting. In this manuscript, we retrospectively analyzed clinical responses to selected salvage IST, including sirolimus, tofacitinib, and subcutaneously administered abatacept and alemtuzumab, in a cohort of 151 patients with aplastic anemia, pure red cell aplasia, large granular lymphocytic leukemia, and other rare hypoproliferative BMFS. Our results indicate significant salvage rates with these agents and differential efficacy in specific clinical scenarios, showing differences in responses in affected lineages and in different disease states. We report that different modalities of IST may have lineage-restricted and overall responses in relapsed or refractory BMFS states, and durable response can be achieved in clinically difficult cases. These findings underscore the need for clinical trials to establish the safety and efficacy of alternative agents as substitute lines of therapy in BMFS.
- 3 November 2026
- Published by Springer Nature in Leukemia
- p. 1-9
Open AccessSalvage therapy for immune-mediated bone marrow failure
Most acquired idiopathic bone marrow failure syndromes (BMFS) are thought to be cytotoxic T cell-mediated and are responsive to immunosuppressive therapies (IST) targeting T cells. However, in addition to frequent relapses, a proportion of cases remain refractory to first- and second-line agents due to a lack of clinical trials in the refractory and relapsed disease setting. Recently, the landscape of IST has expanded significantly, harnessing multiple molecular pathways that could be theoretically useful in the BMFS setting. In this manuscript, we retrospectively analyzed clinical responses to selected salvage IST, including sirolimus, tofacitinib, and subcutaneously administered abatacept and alemtuzumab, in a cohort of 151 patients with aplastic anemia, pure red cell aplasia, large granular lymphocytic leukemia, and other rare hypoproliferative BMFS. Our results indicate significant salvage rates with these agents and differential efficacy in specific clinical scenarios, showing differences in responses in affected lineages and in different disease states. We report that different modalities of IST may have lineage-restricted and overall responses in relapsed or refractory BMFS states, and durable response can be achieved in clinically difficult cases. These findings underscore the need for clinical trials to establish the safety and efficacy of alternative agents as substitute lines of therapy in BMFS.
- Open Access
- 28 September 2026
- Published by MDPI AG in Hematology Reports
- Vol. 18 (5) , 70
Treatment of Acute Myeloid Leukemia in the Elderly
Background: Acute myeloid leukemia (AML) is the most prevalent type of leukemia, which primarily affects older patients. Because the definition of ‘elderly’ AML varies across the literature, from ≥60 years in some cooperative-group studies to a strict ≥ 75-year threshold in the pivotal VIALE-A trial, we adopt ≥ 60 years as our working definition. Despite recent advancements, the 5-year overall survival (OS) of AML patients is just 30% and declines to 5–10% in patients older than 65 years at diagnosis. The main objective of treatment in older individuals is to achieve complete remission (CR) and maintain a good quality of life. Discussion: Traditionally, intensive chemotherapy (IC) has been used for management of AML since the 1970s. Patients older in age are often not eligible for IC due to factors such as advanced age, comorbidities, and disease characteristics such as high-risk cytogenetics and adverse risk mutations. When considering patients for intensive (and alternative) chemotherapy and allogeneic hematopoietic stem cell transplantation (alloHSCT), we need to consider a standardized fitness assessment tool, which would significantly improve our capacity to individualize treatment strategies and design patient-specific clinical trials. Tools such as performance status, the Ferrara criteria, and comprehensive geriatric assessment (CGA) can help evaluate the baseline comorbidity burden in elderly patients. The discovery of hypomethylating agents (HMAs) like azacitidine and decitabine and BCL-2 inhibitors such as venetoclax has been pivotal in the treatment of elderly AML patients unfit for IC. As our knowledge advances in understanding the pathogenesis of AML, we are learning about new genetic mutations and molecular targets that play an important role in the development of AML. In this revised review, we explicitly separate drugs that are FDA-approved and have been studied specifically in older or unfit AML patients from drugs that are approved but lack dedicated efficacy data in this population and from agents that remain investigational; each tier is summarized in a comparative table of results in all-comers versus results in older/unfit patients and limitations. Advances in reduced-intensity conditioning and GVHD prophylaxis have extended allogeneic transplantation to select fit older patients, while low-dose chemotherapy to manage cell count and supportive care remain vital for non-aggressive pathways. Conclusions: In our review, we have outlined current treatment options for older AML patients, with an emphasis on distinguishing which regimens are supported by dedicated evidence in this population, particularly those unfit for IC.
- 28 September 2026
- Published by MDPI AG in Hematology Reports
- Vol. 18 (5) , 70
Open AccessTreatment of Acute Myeloid Leukemia in the Elderly
Background: Acute myeloid leukemia (AML) is the most prevalent type of leukemia, which primarily affects older patients. Because the definition of ‘elderly’ AML varies across the literature, from ≥60 years in some cooperative-group studies to a strict ≥ 75-year threshold in the pivotal VIALE-A trial, we adopt ≥ 60 years as our working definition. Despite recent advancements, the 5-year overall survival (OS) of AML patients is just 30% and declines to 5–10% in patients older than 65 years at diagnosis. The main objective of treatment in older individuals is to achieve complete remission (CR) and maintain a good quality of life. Discussion: Traditionally, intensive chemotherapy (IC) has been used for management of AML since the 1970s. Patients older in age are often not eligible for IC due to factors such as advanced age, comorbidities, and disease characteristics such as high-risk cytogenetics and adverse risk mutations. When considering patients for intensive (and alternative) chemotherapy and allogeneic hematopoietic stem cell transplantation (alloHSCT), we need to consider a standardized fitness assessment tool, which would significantly improve our capacity to individualize treatment strategies and design patient-specific clinical trials. Tools such as performance status, the Ferrara criteria, and comprehensive geriatric assessment (CGA) can help evaluate the baseline comorbidity burden in elderly patients. The discovery of hypomethylating agents (HMAs) like azacitidine and decitabine and BCL-2 inhibitors such as venetoclax has been pivotal in the treatment of elderly AML patients unfit for IC. As our knowledge advances in understanding the pathogenesis of AML, we are learning about new genetic mutations and molecular targets that play an important role in the development of AML. In this revised review, we explicitly separate drugs that are FDA-approved and have been studied specifically in older or unfit AML patients from drugs that are approved but lack dedicated efficacy data in this population and from agents that remain investigational; each tier is summarized in a comparative table of results in all-comers versus results in older/unfit patients and limitations. Advances in reduced-intensity conditioning and GVHD prophylaxis have extended allogeneic transplantation to select fit older patients, while low-dose chemotherapy to manage cell count and supportive care remain vital for non-aggressive pathways. Conclusions: In our review, we have outlined current treatment options for older AML patients, with an emphasis on distinguishing which regimens are supported by dedicated evidence in this population, particularly those unfit for IC.
- Open Access
Longitudinal analysis of tyrosine kinase inhibitor therapy outcomes and BCR‐ABL1 transcript decline velocity in chronic myeloid leukemia: A 16‐year real‐world study
Background: No large, randomized trials have compared three or more tyrosine kinase inhibitors (TKIs) in a single chronic myeloid leukemia (CML) cohort. Most studies are two‐arm comparisons versus imatinib, or rely on indirect methods. Methods: A retrospective cohort study was conducted of 349 patients with chronic‐ and accelerated‐phase CML treated between 2007 and 2023 at Cleveland Clinic centers in Northeast Ohio. Overall survival (OS), event‐free survival (EFS), 12‐month therapeutic milestone achievement, and BCR‐ABL1 transcript decline velocity across first‐, second‐, and third‐line TKIs were compared. Baseline demographics, comorbidities, cytogenetics, and hematologic parameters were collected. Multivariable regression and time‐dependent Cox models were adjusted for confounders and varying therapy initiation times. Results: First‐line TKIs included imatinib (53%), dasatinib (30%), nilotinib (15%), and bosutinib (2%). Median age ranged from 52 to 60 years, most patients were White, and high‐risk cytogenetics were rare. Five‐year OS ranged from 78% for dasatinib to 90% for nilotinib, with nilotinib associated with improved OS (hazard ratio [HR], 0.43) and EFS (HR, 0.48) and the fastest BCR‐ABL1 decline (β = −8.3%) versus imatinib. In second‐ ( n = 181) and third‐line therapy ( n = 91), no significant differences in outcomes were observed. Across all lines, time‐dependent modeling showed improved EFS only for nilotinib (HR, 0.61). Unadjusted OS was higher in patients starting treatment in 2007–2010 versus later periods but differences disappeared after adjustment. Conclusions: Real‐world data indicate that imatinib achieves comparable response rates to newer TKIs, with durable survival. Nilotinib consistently shows faster BCR‐ABL1 decline and improved EFS overall, consistent with prior network meta‐analyses. Lack of improvement in OS over time suggests the need to investigate factors influencing long‐term outcomes in CML.
Open AccessLongitudinal analysis of tyrosine kinase inhibitor therapy outcomes and BCR‐ABL1 transcript decline velocity in chronic myeloid leukemia: A 16‐year real‐world study
Background: No large, randomized trials have compared three or more tyrosine kinase inhibitors (TKIs) in a single chronic myeloid leukemia (CML) cohort. Most studies are two‐arm comparisons versus imatinib, or rely on indirect methods. Methods: A retrospective cohort study was conducted of 349 patients with chronic‐ and accelerated‐phase CML treated between 2007 and 2023 at Cleveland Clinic centers in Northeast Ohio. Overall survival (OS), event‐free survival (EFS), 12‐month therapeutic milestone achievement, and BCR‐ABL1 transcript decline velocity across first‐, second‐, and third‐line TKIs were compared. Baseline demographics, comorbidities, cytogenetics, and hematologic parameters were collected. Multivariable regression and time‐dependent Cox models were adjusted for confounders and varying therapy initiation times. Results: First‐line TKIs included imatinib (53%), dasatinib (30%), nilotinib (15%), and bosutinib (2%). Median age ranged from 52 to 60 years, most patients were White, and high‐risk cytogenetics were rare. Five‐year OS ranged from 78% for dasatinib to 90% for nilotinib, with nilotinib associated with improved OS (hazard ratio [HR], 0.43) and EFS (HR, 0.48) and the fastest BCR‐ABL1 decline (β = −8.3%) versus imatinib. In second‐ ( n = 181) and third‐line therapy ( n = 91), no significant differences in outcomes were observed. Across all lines, time‐dependent modeling showed improved EFS only for nilotinib (HR, 0.61). Unadjusted OS was higher in patients starting treatment in 2007–2010 versus later periods but differences disappeared after adjustment. Conclusions: Real‐world data indicate that imatinib achieves comparable response rates to newer TKIs, with durable survival. Nilotinib consistently shows faster BCR‐ABL1 decline and improved EFS overall, consistent with prior network meta‐analyses. Lack of improvement in OS over time suggests the need to investigate factors influencing long‐term outcomes in CML.
- Open Access
- 6 July 2026
- Published by Elsevier in SSRN Electronic Journal
Major Adverse Cardiovascular Events (MACE) in Cancer Patients Treated With Tirzepatide Compared to Semaglutide: A Target Trial Emulation Using Real-World Data
Background: Patients with cancer have elevated cardiovascular risk but have been underrepresented in cardiovascular outcome trials of incretin-based therapies. We compared cardiovascular outcomes associated with tirzepatide and semaglutide in adults with cancer and type 2 diabetes or overweight/obesity.Methods: We conducted an active-comparator, new-user cohort study emulating a target trial using deidentified electronic health record data from 61 US healthcare organizations. Adults initiating tirzepatide or semaglutide between May 1, 2022, and March 1, 2024, were eligible. Tirzepatide initiators were propensity score matched 1:1 to semaglutide initiators on 76 baseline covariates. The primary outcome was three-point major adverse cardiovascular events (MACE): myocardial infarction, stroke, or cardiovascular death. Cox models estimated hazard ratios (HRs) with 95% CIs over follow-up of up to 30 months.Findings: The matched cohort included 23,536 patients, with 11,768 in each treatment group. Mean age was 59.5 years, 62.9% were female, and mean follow-up was 569 days. MACE occurred in 651 tirzepatide initiators and 842 semaglutide initiators. Tirzepatide initiation was associated with a lower risk of MACE than semaglutide initiation (HR 0.80, 95% CI 0.73–0.89), including lower risks of myocardial infarction (HR 0.79, 95% CI 0.68–0.92) and stroke (HR 0.86, 95% CI 0.75–0.99). Cardiovascular death did not differ significantly between groups. Tirzepatide was also associated with lower risks of heart failure exacerbation, all-cause hospitalization, and all-cause mortality.Interpretation: Tirzepatide initiation was associated with lower cardiovascular risk than semaglutide initiation in adults with cancer and cardiometabolic conditions. Prospective confirmation is warranted before these findings inform treatment selection.
- 6 July 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessMajor Adverse Cardiovascular Events (MACE) in Cancer Patients Treated With Tirzepatide Compared to Semaglutide: A Target Trial Emulation Using Real-World Data
Background: Patients with cancer have elevated cardiovascular risk but have been underrepresented in cardiovascular outcome trials of incretin-based therapies. We compared cardiovascular outcomes associated with tirzepatide and semaglutide in adults with cancer and type 2 diabetes or overweight/obesity.Methods: We conducted an active-comparator, new-user cohort study emulating a target trial using deidentified electronic health record data from 61 US healthcare organizations. Adults initiating tirzepatide or semaglutide between May 1, 2022, and March 1, 2024, were eligible. Tirzepatide initiators were propensity score matched 1:1 to semaglutide initiators on 76 baseline covariates. The primary outcome was three-point major adverse cardiovascular events (MACE): myocardial infarction, stroke, or cardiovascular death. Cox models estimated hazard ratios (HRs) with 95% CIs over follow-up of up to 30 months.Findings: The matched cohort included 23,536 patients, with 11,768 in each treatment group. Mean age was 59.5 years, 62.9% were female, and mean follow-up was 569 days. MACE occurred in 651 tirzepatide initiators and 842 semaglutide initiators. Tirzepatide initiation was associated with a lower risk of MACE than semaglutide initiation (HR 0.80, 95% CI 0.73–0.89), including lower risks of myocardial infarction (HR 0.79, 95% CI 0.68–0.92) and stroke (HR 0.86, 95% CI 0.75–0.99). Cardiovascular death did not differ significantly between groups. Tirzepatide was also associated with lower risks of heart failure exacerbation, all-cause hospitalization, and all-cause mortality.Interpretation: Tirzepatide initiation was associated with lower cardiovascular risk than semaglutide initiation in adults with cancer and cardiometabolic conditions. Prospective confirmation is warranted before these findings inform treatment selection.
- Open Access
Cytokine receptor and JAK/STAT pathway mutations in acute myeloid leukemia: Prevalence and clinical impact
Background: Mutations in cytokine receptor and JAK/STAT; Cy‐JAK/STAT) signaling genes drive myeloproliferative neoplasms (MPNs) but remain incompletely characterized in acute myeloid leukemia (AML). The authors evaluated the prevalence, clinical presentation, and prognostic significance of Cy‐JAK/STAT pathway mutations in patients with AML and compared outcomes across disease ontogeny. Methods: In total, 971 adults with newly diagnosed AML who were treated at the Cleveland Clinic between January 2015 and September 2023 were retrospectively analyzed. Baseline next‐generation sequencing was queried for eight Cy‐JAK/STAT pathway genes: CALR , JAK1 , JAK2 , JAK3 , MPL , SH2B3 , STAT3 , and STAT5B . Outcomes included composite‐complete remission (complete remission or complete remission with incomplete hematologic recovery), event‐free survival, and overall survival. In a prespecified subgroup of patients who had baseline molecular testing results available ( n = 621), those who had blast‐phase MPN ( n = 68), de novo AML with JAK2 / CALR / MPL mutations ( n = 23), and de novo AML without Cy‐JAK/STAT mutations ( n = 530) were compared. Results: Mutation frequencies for the eight genes were as follows: JAK2, 43 of 625 patients (6.9%); CALR, nine of 623 (1.4%); SH2B3, eight of 392 (2.0%); JAK3, five of 439 (1.1%); MPL, one of 639 (0.2%); and STAT5B, one of 390 (0.3%); no JAK1 or STAT3 mutations were detected. The median follow‐up among survivors was 40.9 months, and the median overall survival was 12 months. JAK2‐mutated AML was associated with higher cardiovascular comorbidity, lower complete remission/complete remission with incomplete hematologic recovery rates (32% vs. 54%), and inferior overall survival ( p < .05), but not on multivariable analysis. In subgroup analyses, patients who had blast‐phase MPN had the lowest response rate (13%) and the poorest survival; whereas patients who had de novo AML with JAK2 , CALR , or MPL mutations had intermediate outcomes versus those who had mutation‐negative, de novo AML (41% vs. 57% complete remission). Conclusions: Cy‐JAK/STAT pathway mutations are uncommon in AML, but each mutation has distinct biologic and clinical characteristics. The worse survival observed in patients with JAK2 ‐mutated AML largely appeared to be driven by the co‐occurrence of high‐risk characteristics. Blast‐phase MPN was associated with a dismal prognosis.
Open AccessCytokine receptor and JAK/STAT pathway mutations in acute myeloid leukemia: Prevalence and clinical impact
Background: Mutations in cytokine receptor and JAK/STAT; Cy‐JAK/STAT) signaling genes drive myeloproliferative neoplasms (MPNs) but remain incompletely characterized in acute myeloid leukemia (AML). The authors evaluated the prevalence, clinical presentation, and prognostic significance of Cy‐JAK/STAT pathway mutations in patients with AML and compared outcomes across disease ontogeny. Methods: In total, 971 adults with newly diagnosed AML who were treated at the Cleveland Clinic between January 2015 and September 2023 were retrospectively analyzed. Baseline next‐generation sequencing was queried for eight Cy‐JAK/STAT pathway genes: CALR , JAK1 , JAK2 , JAK3 , MPL , SH2B3 , STAT3 , and STAT5B . Outcomes included composite‐complete remission (complete remission or complete remission with incomplete hematologic recovery), event‐free survival, and overall survival. In a prespecified subgroup of patients who had baseline molecular testing results available ( n = 621), those who had blast‐phase MPN ( n = 68), de novo AML with JAK2 / CALR / MPL mutations ( n = 23), and de novo AML without Cy‐JAK/STAT mutations ( n = 530) were compared. Results: Mutation frequencies for the eight genes were as follows: JAK2, 43 of 625 patients (6.9%); CALR, nine of 623 (1.4%); SH2B3, eight of 392 (2.0%); JAK3, five of 439 (1.1%); MPL, one of 639 (0.2%); and STAT5B, one of 390 (0.3%); no JAK1 or STAT3 mutations were detected. The median follow‐up among survivors was 40.9 months, and the median overall survival was 12 months. JAK2‐mutated AML was associated with higher cardiovascular comorbidity, lower complete remission/complete remission with incomplete hematologic recovery rates (32% vs. 54%), and inferior overall survival ( p < .05), but not on multivariable analysis. In subgroup analyses, patients who had blast‐phase MPN had the lowest response rate (13%) and the poorest survival; whereas patients who had de novo AML with JAK2 , CALR , or MPL mutations had intermediate outcomes versus those who had mutation‐negative, de novo AML (41% vs. 57% complete remission). Conclusions: Cy‐JAK/STAT pathway mutations are uncommon in AML, but each mutation has distinct biologic and clinical characteristics. The worse survival observed in patients with JAK2 ‐mutated AML largely appeared to be driven by the co‐occurrence of high‐risk characteristics. Blast‐phase MPN was associated with a dismal prognosis.
- Open Access
- 11 July 2025
- Published by Wiley in American Journal of Hematology
- Vol. 100 (9) , 1577-1589
Impact of Cytogenetic Response to Therapy on Long‐Term Survival in Acute Myeloid Leukemia
Prognostication in acute myeloid leukemia (AML) relies on clinical, molecular, and cytogenetic factors. In this retrospective study, we examined the impact of different levels of cytogenetic response on overall survival (OS) and event‐free survival (EFS) in AML. Among 973 adult AML patients treated at Cleveland Clinic (5/2017–9/2023), 563 patients had baseline cytogenetic data and post‐treatment response assessment available. Based on baseline and response cytogenetic status, patients were categorized into: normal to normal (NL‐Cy to NL‐Cy, n = 221, 39%), normal or abnormal to gain (NL/Abnl‐Cy to Gain‐Cy, n = 46, 8.2%), abnormal to persistent (Abnl‐Cy to Persistent‐Cy, n = 81, 14%), abnormal to partial response (Abnl‐Cy to Partial‐Cy, n = 20, 3.6%), and abnormal to complete response (Abnl‐Cy to NL‐Cy, n = 195, 35%). Landmark analysis was used to account for post‐treatment assessments. The cohort had a median age of 62 years (interquartile range: 52–69), 256 females (45%), 90% were White, and median follow‐up of 45.8 months (range: 0.73–191.3). The median OS and hazard ratios (HRs) from multivariable regression analysis were as follows: NL‐Cy to NL‐Cy: 37 months (95% CI: 27–91), HR = reference; NL/Abnl‐Cy to Gain‐Cy: 14 months (95% CI: 8.6–30), HR = 1.5 (95% CI: 0.99–2.39); Abnl‐Cy to Persistent‐Cy: 13 months (95% CI: 12–18), HR = 1.61 (95% CI: 1.13–2.31); Abnl‐Cy to Partial‐Cy: 25 months (95% CI: 14‐NC), HR = 0.76 (95% CI: 0.39–1.49); and Abnl‐Cy to NL‐Cy: 27 months (95% CI: 19–101), HR = 1.25 (95% CI: 0.93–1.68) (p = 0.038). Achieving cytogenetic remission, complete or partial, was associated with better survival outcomes. These findings highlight the importance of monitoring cytogenetic responses to inform treatment decisions and support integrating cytogenetic response into risk‐adapted, personalized AML management strategies.
- 11 July 2025
- Published by Wiley in American Journal of Hematology
- Vol. 100 (9) , 1577-1589
Open AccessImpact of Cytogenetic Response to Therapy on Long‐Term Survival in Acute Myeloid Leukemia
Prognostication in acute myeloid leukemia (AML) relies on clinical, molecular, and cytogenetic factors. In this retrospective study, we examined the impact of different levels of cytogenetic response on overall survival (OS) and event‐free survival (EFS) in AML. Among 973 adult AML patients treated at Cleveland Clinic (5/2017–9/2023), 563 patients had baseline cytogenetic data and post‐treatment response assessment available. Based on baseline and response cytogenetic status, patients were categorized into: normal to normal (NL‐Cy to NL‐Cy, n = 221, 39%), normal or abnormal to gain (NL/Abnl‐Cy to Gain‐Cy, n = 46, 8.2%), abnormal to persistent (Abnl‐Cy to Persistent‐Cy, n = 81, 14%), abnormal to partial response (Abnl‐Cy to Partial‐Cy, n = 20, 3.6%), and abnormal to complete response (Abnl‐Cy to NL‐Cy, n = 195, 35%). Landmark analysis was used to account for post‐treatment assessments. The cohort had a median age of 62 years (interquartile range: 52–69), 256 females (45%), 90% were White, and median follow‐up of 45.8 months (range: 0.73–191.3). The median OS and hazard ratios (HRs) from multivariable regression analysis were as follows: NL‐Cy to NL‐Cy: 37 months (95% CI: 27–91), HR = reference; NL/Abnl‐Cy to Gain‐Cy: 14 months (95% CI: 8.6–30), HR = 1.5 (95% CI: 0.99–2.39); Abnl‐Cy to Persistent‐Cy: 13 months (95% CI: 12–18), HR = 1.61 (95% CI: 1.13–2.31); Abnl‐Cy to Partial‐Cy: 25 months (95% CI: 14‐NC), HR = 0.76 (95% CI: 0.39–1.49); and Abnl‐Cy to NL‐Cy: 27 months (95% CI: 19–101), HR = 1.25 (95% CI: 0.93–1.68) (p = 0.038). Achieving cytogenetic remission, complete or partial, was associated with better survival outcomes. These findings highlight the importance of monitoring cytogenetic responses to inform treatment decisions and support integrating cytogenetic response into risk‐adapted, personalized AML management strategies.
- 19 May 2025
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 25 (9) , e668-e674.e9
Comparing Outcomes of First-Line Intensive Chemotherapeutic Regimens in Adult Patients With Acute Lymphoblastic Leukemia at a Tertiary Center
- 19 May 2025
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 25 (9) , e668-e674.e9
Comparing Outcomes of First-Line Intensive Chemotherapeutic Regimens in Adult Patients With Acute Lymphoblastic Leukemia at a Tertiary Center